Nexstim Plc Has Agreed on a Digitalization and Innovation Loan with Finnvera to Finance Product Development Project
June 27 2024 - 9:45AM
Nexstim Plc Has Agreed on a Digitalization and Innovation Loan with
Finnvera to Finance Product Development Project
Company Announcement, Helsinki, 27 June 2024 at 4:45 PM
(EEST)
Nexstim Plc Has Agreed on a Digitalization and
Innovation Loan with Finnvera to Finance Product Development
Project
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has agreed on
an EUR 1.5 million digitalization and innovation loan with
Finnvera. The loan has been implemented in cooperation with the
European Investment Fund. The Company intends to use the loan for
financing product development work of its NBS 6 system. The loan
period is six years, and the digitalization and innovation loan
program’s loan conditions apply. More information about the loan
program is available at
https://www.finnvera.fi/eng/financing/loans/digitalisation-and-innovation-loan.
Mikko Karvinen, CEO of Nexstim, comments: “One of Nexstim’s
strategic goals for 2024 is launching diagnostic applications as
part of the new NBS 6 system. NBS 6 is a new combination system
built on Nexstim's unique, clinically established technology and
the modular system concept makes it easy to add new features to
existing systems. The new system creates long-term value for
Nexstim's customers and investors alike, and we’re very happy of
Finnvera’s debt financing for this important product development
work.”
Further information is available on the website
www.nexstim.com, or by
contacting:
Mikko Karvinen, CEO+358 50 326
4101mikko.karvinen@nexstim.com
The Company’s Certified Advisor is Carnegie Investment Bank AB
(publ).
About Nexstim Plc
Nexstim is a Finnish, globally operating
growth-oriented medical technology company. Our mission is to
enable personalized and effective diagnostics and therapies for
challenging brain diseases and disorders.
Nexstim has developed a world-leading
non-invasive brain stimulation technology for navigated
transcranial magnetic stimulation (nTMS) with highly sophisticated
3D navigation providing accurate and personalized targeting of the
TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on
commercialization of the Navigated Brain Stimulation (NBS) system.
The NBS System 5 is the only FDA cleared and CE marked navigated
TMS system for pre-surgical mapping of the speech and motor
cortices of the brain.
Nexstim’s Therapy Business markets and sells the
NBS System 6 which is FDA cleared for marketing and commercial
distribution for the treatment of major depressive disorder (MDD)
in the United States. In Europe, the NBS 6 system is CE marked for
the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North
Growth Market Finland.
For more information, please visit
www.nexstim.com
- Nexstim Plc_Company announcement_Loan_27062024_FINAL_EN